Transcranial Direct Current Stimulation for Posterior Cortical Atrophy
(PCA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether high-definition transcranial direct current stimulation (HD-tDCS), a type of non-invasive brain stimulation, can improve visual and cognitive abilities in people with posterior cortical atrophy (PCA), a condition affecting vision and cognition. Participants will be randomly assigned to receive either real or sham (fake) HD-tDCS over four days, with an option to continue with real HD-tDCS for up to 26 weeks. The trial is ideal for individuals with symptoms consistent with PCA, who speak English fluently, and have been on stable medication for at least four weeks. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research that could enhance understanding and treatment of PCA.
Do I need to stop my current medications to join the trial?
The trial requires that you have been stable on your current medications for at least about 4 weeks before joining. This means you should not change your medications right before or during the trial.
What prior data suggests that high-definition transcranial direct current stimulation (HD-tDCS) is safe for individuals with posterior cortical atrophy (PCA)?
Research has shown that High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is generally safe. Studies suggest it can aid conditions like chronic insomnia by improving sleep. These studies report no major safety issues with HD-tDCS.
Most participants experience only mild side effects, such as slight tingling or itching where electrodes contact the scalp. Serious side effects are rare. As a non-invasive treatment, HD-tDCS does not involve surgery or penetrate deeply into the body, making it less risky than invasive procedures.
In summary, research indicates that HD-tDCS has a good safety record, offering a potentially safe option for those considering participation in trials involving this treatment.12345Why are researchers excited about this trial?
Unlike the standard treatments for Posterior Cortical Atrophy, which typically involve medications for managing symptoms like memory loss and vision problems, High-Definition Transcranial Direct Current Stimulation (HD-tDCS) uses a non-invasive technique that targets brain activity directly. This method applies a low electrical current to specific areas of the brain, potentially enhancing cognitive function and slowing disease progression. Researchers are excited about HD-tDCS because it offers a novel approach that could provide more immediate and direct benefits compared to conventional drug therapies, with the added convenience of being administered at home or in clinical settings.
What evidence suggests that high-definition transcranial direct current stimulation is effective for posterior cortical atrophy?
Research has shown that high-definition transcranial direct current stimulation (HD-tDCS) might improve visual and cognitive skills. HD-tDCS has also shown promise in helping individuals with chronic insomnia sleep better and feel less tired during the day, suggesting it might affect brain activity in other beneficial ways. Although limited data exists specifically for posterior cortical atrophy (PCA), HD-tDCS targets brain areas potentially impacted by this condition. In this trial, participants will receive either real or sham HD-tDCS stimulation through randomization. Early signs indicate that HD-tDCS can alter brain function, which might benefit those with PCA. This makes it a treatment worth exploring for its potential positive effects on the brain.14567
Who Is on the Research Team?
Benjamin Hamstead, PhD
Principal Investigator
University of Michigan
Are You a Good Fit for This Trial?
This trial is for individuals with Posterior Cortical Atrophy who are interested in exploring a non-invasive brain stimulation treatment. Participants will be randomly assigned to receive either actual HD-tDCS sessions or sham (placebo) sessions, and have the option for additional real treatments after the initial phase.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Randomized Treatment
Participants receive either real or sham HD-tDCS for 8 sessions over 4 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label Extension (optional)
Participants may opt into continuation of real HD-tDCS treatment for up to 26 weeks
What Are the Treatments Tested in This Trial?
Interventions
- High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan
Lead Sponsor